ONCAlert | Upfront Therapy for mRCC

Second-Line Immunotherapy Combos in MORPHEUS Trial for Advanced Urothelial Carcinoma

Alexandra Drakaki, MD, PhD
Published Online: 10:00 PM, Fri February 14, 2020

Alexandra Drakaki, MD, PhD, assistant professor of medicine, hematology, and oncology, and medical director of Genitourinary Oncology Program, University of California, Los Angeles, discusses the goals of the phase Ib/II MORPHEUS trial, which is an umbrella study evaluating several second-line immunotherapy combinations in patients with advanced or metastatic urothelial carcinoma.

The aim of the trial is to identify an optimal combination that will enhance the immune system, as well as elicit tumor infiltration and immune cell activation, Drakaki explains. Researchers are interested in determining the mechanisms of resistance, and how future combinations can be modified for patients. The benefit of this trial is that arms that are not showing efficacy will be closed, and new arms will open to evaluate their efficacy, she adds.

The primary endpoint of the MORPHEUS trial is objective response rate; secondary endpoints are progression-free survival, overall survival (OS), 12-month OS rate, and safety. Researchers will also conduct biomarker analyses to determine why select patients may respond to certain regimens in the trial.

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.